Kendra Kimmons - Amedisys VP Relations
| AMED Stock | USD 91.41 0.18 0.20% |
Insider
Kendra Kimmons is VP Relations of Amedisys
| Address | 3854 American Way, Baton Rouge, LA, United States, 70816 |
| Phone | 225 292 2031 |
| Web | https://www.amedisys.com |
Amedisys Management Efficiency
The company has return on total asset (ROA) of 0.0627 % which means that it generated a profit of $0.0627 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0721 %, meaning that it created $0.0721 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.10, whereas Return On Tangible Assets are projected to grow to (0.01). At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 19.9 M, whereas Net Tangible Assets are projected to grow to (288.1 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Gregory Carmichael | Encompass Health Corp | 59 | |
| Anthony Hernandez | Encompass Health Corp | 58 | |
| Jennifer CPA | Pennant Group | 55 | |
| Matthew Deans | Option Care Health | N/A | |
| Robin Doerr | InnovAge Holding Corp | 60 | |
| W Adams | National HealthCare | 73 | |
| L Shaw | Encompass Health Corp | 75 | |
| Rob Borella | InnovAge Holding Corp | N/A | |
| JD Kennedy | InnovAge Holding Corp | 63 | |
| Andrew Brophy | Healthcare Services Group | 34 | |
| Matthew Peterson | Universal Health Services | 54 | |
| Barbara CPA | InnovAge Holding Corp | 61 | |
| Terrance Williams | Encompass Health Corp | 52 | |
| Derek Bunker | Pennant Group | 36 | |
| Maria Lozzano | InnovAge Holding Corp | 44 | |
| Andrew Honeybone | Acadia Healthcare | N/A | |
| Crissy Carlisle | Enhabit | 52 | |
| Brent Guerisoli | Pennant Group | 43 | |
| Christopher Hunter | Acadia Healthcare | 56 | |
| Dan Peoples | Enhabit | N/A | |
| Brett Michalak | Option Care Health | N/A | |
Management Performance
| Return On Equity | 0.0721 | ||||
| Return On Asset | 0.0627 |
Amedisys Leadership Team
Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael North, Senior Vice President - Operations | ||
| John Nugent, Chief Officer | ||
| Pete Hartley, CTO Systems | ||
| Kendra Kimmons, VP Relations | ||
| Jennifer Griffin, Deputy VP | ||
| Janet Britt, VP Collections | ||
| Francis Mayer, Senior Development | ||
| Keith Blanchard, Acting Officer | ||
| Richard Ashworth, CEO President | ||
| Scott CPA, COO, VP | ||
| Allyson Guidroz, Chief Officer | ||
| Scott Ginn, Chief Accounting Officer | ||
| Denise Bohnert, Chief Officer | ||
| Paul Kusserow, CEO and President and Director | ||
| Caitlin Franklin, Acting Officer | ||
| Nick Muscato, Vice President of Strategic Finance | ||
| Adam Holton, Chief Officer |
Amedisys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0721 | ||||
| Return On Asset | 0.0627 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 3.21 B | ||||
| Shares Outstanding | 32.75 M | ||||
| Shares Owned By Insiders | 2.37 % | ||||
| Shares Owned By Institutions | 90.44 % | ||||
| Number Of Shares Shorted | 2.18 M | ||||
| Price To Earning | 15.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.35) | Earnings Share 2.52 | Revenue Per Share 71.004 | Quarterly Revenue Growth 0.057 | Return On Assets 0.0627 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.